RECIST Response Evaluation Criteria in Solid Tumors

Response Evaluation Criteria in Solid Tumors (RECIST)... 

Traditional methods for the evaluation of tumor response to therapy have been size reduction on CT through the application of the WHO or Response Evaluation Criteria in Solid Tumors (RECIST) criteria [73, 74]. However, some pitfalls may occur when those methods based on CT dimensional changes are applied to Y therapy. First, RECIST or WHO criteria do not allow for the use of PET scanning in the follow-up evaluation, thereby ignoring the functional nature of the residual tissue. Further-... 

A Phase-2 clinical study of IMO-2055 monotherapy in renal cell carcinoma with four arms has been reported [120]. In this study treatment, naive and second-line patients received IMO-2055 subcutaneously at either 0.16 or 0.64 mg/kg/week. The median PFS was 4.5 and 1.9 months for the 0.16- and 0.64-mg/kg/week treatment-naive patients, and 3.4 and 4.3 months for the 0.16- and 0.64-mg/kg/ week second-line patients, respectively. Median overall survival was 23.5 months over aU arms, with 58% of patients having stable disease. Two patients have shown partial responses. Seven patients received weekly IMO-2055 treatment for at least 1 year. IMO-2055 treatment was generally well tolerated at the dose levels studied. The primary objective of tumor response, based on response evaluation criteria in solid tumors (RECIST), was not achieved in the study [120]. 

New forms of chemotherapeutic treatment may result in dramatic reduction and advanced necrosis of the lesions on subsequent follow-up CT. Tumour size, as judged by Response Evaluation Criteria of Solid Tumors (RECIST) criteria, may not adequately define response to therapy when the predominant... 

Fusai G, Davidson BR (2003b) Management of colorectal liver metastases. Colorectal Dis 5 2-23 Gazelle GS, Hunink MG, Kuntz KM, et al (2003) Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma a state-transition Monte Carlo decision analysis. Ann Surg 237 544-555 Gehan EA, Tefft MC (2000) Will there be resistance to the RECIST (response evaluation criteria in solid tumors) J Natl Cancer Inst 92 179-181... 

---